Yihao Li

Research Chief @ BeOne Medicines

About

Cancer biologist uncovering therapeutic vulnerabilities and dissecting molecular mechanisms underlying drug response and resistance. Drug discovery leader leveraging signal transduction, functional genomics, epigenomics, and high-throughput technologies to drive target discovery and therapeutic innovation.Leading early discovery, technology development, and translational research across kinase signaling, epigenetic regulators, immune checkpoints, and cytokine biology.Over 10 years of experience in oncology research and drug discovery. Previously trained with Myles Brown at Dana-Farber Cancer Institute and received Ph.D. training under Peter ten Dijke at Leiden University Medical Center.

Country

China

City

Shanghai

Industry

Pharmaceuticals

Skill

Experience

Research Chief

BeOne Medicines

2022-8 - Present · 4 yrs 2 mos

Shanghai, China

Instructor

Dana-Farber Cancer Institute

2022-3 - 2022-8 · 6 mos

United States

RNA epigenetic dysregulation driving tumorigenesis *Integrated functional genomics, single-cell analysis, and organoid models to identify regulators of mammary epithelial fitness and differentiation. *Defined a novel m6A-mediated innate immune regulatory axis (METTL3–m6A–transposon–IFN/STAT) governing epithelial hierarchy and early tumorigenesis (Li et al., PNAS, 2025).

Research Fellow

Dana-Farber Cancer Institute

2016-10 - 2022-3 · 5 yrs 6 mos

Boston, MA

Mechanisms mediating therapeutic resistance to FGFR inhibitors *Identified treatment-induced epigenetic and metabolic feedback mechanisms driving resistance to FGFR inhibitors in breast cancer. *Revealed a combinatorial therapeutic strategy with translational implications for FGFR-driven cancers (Li et al., Nature Cell Biology, 2021).